Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients

UCB

Status: Completed

Conditions: Hypertension

Treatments: Drug: Lercanidipine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00160498

Ler 25-03

Details and patient eligibility

About

A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI): 18.0 - 24.9 or 30.0 - 39.9 kg/m2 (extremes included);
• Essential hypertension I or II WHO:
• 140 mmHg ≤ BPs ≤ 179 mmHg and BPd ≤ 109 mmHg at the end of the placebo run-in phase;

Exclusion criteria

• Secondary hypertension;
• Diabetes mellitus type 1, insulin dependent diabetes mellitus type 2, fasting blood glucose ≥ 160 mg/dl;
• Subjects keeping to a hypocaloric diet (except special diet for diabetics) to reduce body weight;
• History or presence of angioneurotic oedema;
• Subjects developing a hypertensive crisis during wash-out or placebo run-in period;